Raphael Pharmaceutical (RAPH) EBITDA (2020 - 2024)
Raphael Pharmaceutical (RAPH) reported EBITDA of -$394000.0 for Q4 2024, down 394.03% on a YoY basis from $134000.0 in Q1 2024, and down 23.51% sequentially from -$319000.0 in Q3 2024.
Raphael Pharmaceutical (RAPH) EBITDA (2020 - 2024) Analysis & Trends
Raphael Pharmaceutical (RAPH) has 5 years of EBITDA data on file, last reported at -$394000.0 in Q4 2024.
- For the quarter ending Q4 2024, EBITDA fell 394.03% year-over-year to -$394000.0; the trailing twelve-month figure through Dec 2024 stood at -$1.5 million (down 18.63% YoY), and the FY2025 full-year result was -$1.2 million, up 17.5% from the prior year.
- EBITDA fell to -$394000.0 in Q4 2024, from -$319000.0 in the prior quarter.
- In the past five years, EBITDA ranged from a high of $134000.0 in Q4 2023 to a low of -$1.4 million in Q3 2022.
- A 5-year average of -$467882.4 and a median of -$394000.0 in 2024 frame the typical range for EBITDA.
- Across the five-year window, EBITDA jumped 112.14% in 2023 and tumbled 394.03% in 2024, its largest moves.
- Tracing RAPH's EBITDA over 5 years: stood at -$227000.0 in 2020, then plunged by 152.86% to -$574000.0 in 2021, then tumbled by 92.33% to -$1.1 million in 2022, then soared by 112.14% to $134000.0 in 2023, then plunged by 394.03% to -$394000.0 in 2024.
- Business Quant data shows RAPH's EBITDA at -$394000.0 in Q4 2024, -$319000.0 in Q3 2024, and -$249000.0 in Q2 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 652.00 Mn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 833.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | -2.65 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 325.80 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | -79.70 Mn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 193.40 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 291.00 Mn |
| 10 | Raphael Pharmaceutical | 27.37 Mn | 27.33 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | -394,000.00 |
| Sep 30, 2024 | -319,000.00 |
| Jun 30, 2024 | -249,000.00 |
| Mar 31, 2024 | -547,000.00 |
| Dec 31, 2023 | 134,000.00 |
| Sep 30, 2023 | -729,000.00 |
| Jun 30, 2023 | -419,000.00 |
| Mar 31, 2023 | -258,000.00 |
| Dec 31, 2022 | -1.10 Mn |
| Sep 30, 2022 | -1.43 Mn |
| Jun 30, 2022 | -612,000.00 |
| Mar 31, 2022 | -175,000.00 |
| Dec 31, 2021 | -574,000.00 |
| Sep 30, 2021 | -418,000.00 |
| Jun 30, 2021 | -385,000.00 |
| Mar 31, 2021 | -252,000.00 |
| Dec 31, 2020 | -227,000.00 |